表紙:細胞・遺伝子治療市場と取引分析(2023年):資金調達、提携、M&A、技術移転、IPO、その他の取引
市場調査レポート
商品コード
1277030

細胞・遺伝子治療市場と取引分析(2023年):資金調達、提携、M&A、技術移転、IPO、その他の取引

Cell and Gene Therapy Market and Deals Analysis, 2023: Financings, Partnering, Mergers and Acquisitions, Tech Transfers, IPOs, and Other Deals

出版日: | 発行: Kalorama Information | ページ情報: 英文 261 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.52円
細胞・遺伝子治療市場と取引分析(2023年):資金調達、提携、M&A、技術移転、IPO、その他の取引
出版日: 2023年05月22日
発行: Kalorama Information
ページ情報: 英文 261 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の細胞・遺伝子治療の市場規模は、2022年に400億米ドルという驚異的な金額に達しています。細胞・遺伝子治療(CGT)に関連する企業と他の資金提供団体との取引量は増加しており、企業は2021年レベルの投資額から減少しているにもかかわらず、多額の投資を受け続けています。

当レポートは、細胞および遺伝子治療企業のディールメーキングと市場機会を追跡しています。最近、細胞・遺伝子治療(CGT)に関連する分野に多くの注目が集まっています。

KaloramaのCGT案件は、2022年に400億米ドルという驚異的な金額に達しています

遺伝子治療と細胞治療のコンセプトは何十年も前から研究されてきましたが、初期には大きな課題がありました。その後、CRISPRや次世代シーケンサー(NGS)などのツールが徐々に導入され、細胞治療や遺伝子治療は非常に活発な分野となりました。現在では、実績のある多くの治療法が承認されています。

新しいツールによって業界への参入障壁が低くなったため、1,500社以上の企業が誕生したり、関わったりしています。

以下は、本レポートの情報の一部です:

  • 最も活発なディールメーキングを行う企業
  • 2021年4月~2023年3月、1カ月あたりのディール数
  • タイプ別ディール - 技術/調査/戦略的コラボレーション、ベンチャーキャピタル/民間投資、買収、合併、戦略的投資、ライセンシング、株式公開/SPAC、製造、サプライチェーン、アウトリーチ、慈善活動、教育、流通、共同マーケティング、スピンアウト、再編、取引の締結/終了、ジョイントベンチャー、訴訟の決裂
  • ベンチャーキャピタルとプライベートファンディングの月別案件数(2021年1月~2023年3月)(総数
  • ベンチャーキャピタル/プライベートファンディングの地域別シェア【北米、欧州、APAC、世界のその他諸国】(%)
  • M&Aの総件数(月別
  • 平均M&A金額(四半期別)[2021年第1四半期~2023年第1四半期](単位:百万米ドル
  • M&A一覧 [企業1, 企業2, 詳細, 金額, マイルストーン付, 日付] (英語)
  • 最も頻繁に行われた案件の種類(四半期別、カテゴリー別[技術/調査/戦略的共同研究、ベンチャーキャピタル/民間投資、買収/合併/戦略的投資、ライセンシング、株式公開/SPAC、製造/サプライチェーン](総数)
  • 買収/合併/戦略的投資で最もアクティブな企業
  • 全体的な取引、共同研究において最も活発な企業
  • 細胞・遺伝子治療薬の推定市場予測:タイプ別(遺伝子治療薬、細胞治療薬)
  • 地域別推定市場予測(北米、EU、APAC、その他)
  • CGTの疾患カテゴリー別推定市場予測(がん、その他)

主要な市場調査出版社が発行するレポートで、2023年に存在する細胞および遺伝子治療の取引空間をこれほど包括的に扱ったものはありません。細胞および遺伝子治療は競争の激しいマーケットであるため、本レポートでは数百の企業を参照しています。

目次

第1章 エグゼクティブサマリー

第2章 ベンチャーキャピタルと民間資金

第3章 戦略的投資

  • 細胞および遺伝子治療への戦略的投資
  • 最も活発な企業

第4章 IPO、FPO、SPAC

  • 北米では収益の大部分がIPO、FPO、SPACから得られる

第5章 合併・買収(M&A)

  • 平均金額は低下するもM&A件数は増加
  • 最も活発な企業

第6章 技術/調査/戦略的コラボレーション

  • CGT市場では幅広いコラボレーションが見られる
  • 最も活発な企業

第7章 ライセンシング

  • 細胞および遺伝子治療市場における安定したライセンシングレベル
  • 最も活発な企業

第8章 製造とサプライチェーン

  • CGTにおける製造およびサプライチェーン管理活動の大幅な成長
  • 最も活発な企業

第9章 公的支援、教育、慈善活動

  • CGT市場は公的支援、患者/消費者/研修生の教育、慈善活動にあまり焦点を当てていない

第10章 流通と共同マーケティング

  • CGTの流通と共同マーケティング取引の概要
  • 最も活発な企業

第11章 その他-JV、再編、解散、スピンオフ

  • 細胞治療および遺伝子治療に影響を与える他のタイプの取引を見てみる

第12章 その他- 新しい施設、拡張。不動産

  • 拡張、新施設および関連するお知らせ

付録:細胞および遺伝子治療の市場評価

  • 市場の見通し、2022年~2032年
  • 地域別市場
  • 上市済み製品
  • 細胞および遺伝子治療の主要企業
目次
Product Code: 23-022c

This report, Kalorama's “Cell and Gene Deals and Market Analysis ”, tracks the dealmaking and market opportunity for cell and gene therapy companies. A lot of attention is being given to the areas related to cell and gene therapy (CGT) recently. Kalorama's latest report finds that the volume of deals between companies and other funding entities involving CGT is up, and companies have continued to receive large amounts of investment despite a decline from 2021 levels of investment.

Kalorama's CGT deals amounted to a staggering $40 billion in 2022.

While the concepts of gene therapy and cell therapy have been investigated for decades, there were major challenges in the early years. Through incremental progress, and the gradual introduction of enabling tools such as CRISPR and next-generation sequencing (NGS), cell and gene therapy has emerged into a highly active area. There are now many approved therapies with proven track records.

As the new tools have lowered the barriers to entry for the industry, over 1,500 companies have been created or have become involved.

The following is just some of the information in this report:

  • Most Active Deal-Making Companies
  • Deals per Month, April 2021-March 2023
  • Deals by Type - Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation
  • Venture Capital and Private Funding Deals by Month, January 2021-March 2023 (Total count)
  • Regional Venture Capital/Private Funding Shares [North America, Europe, APAC, Rest of World] (%)
  • Total Number of Mergers and Acquisitions, By Month
  • Average Merger/Acquisition Amount, By Quarter [Q1 2021-Q1 2023] ($M)
  • List of M&As [Company 1, Company 2, Details, Amount, w/Milestones, Date]
  • Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (Total number)
  • Most Active Companies in Acquisition/Merger/ Strategic Investment
  • Most Active Companies in Overall Deals, Collaborations
  • Estimated Market Forecasts for Cell and Gene Therapies by Type (Gene Therapy, Cell Therapy)
  • Estimated Market Forecasts by Region (North America, EU, APAC, Other)
  • Estimated Market Forecasts for CGT by Disease Category (Oncology, Other)

No report published by a major market research publisher has tackled the Cell and Gene Therapy dealmaking space as it exists in 2023 in a more comprehensive fashion. As Cell and Gene Therapy is a highly competitive marketplace, hundreds of companies are referenced in this report.

Table of Contents

Chapter 1: Executive Summary

  • Introduction
  • $40.2 Billion in Funding During 2022
    • Figure 1-1: Total Deals per Month, April 2021-March 2023 (Total count)
    • Figure 1-2: Total Deals per Month by Type, Apr 2021-Mar 2023 [VC/ Private, IPO/FPO/SPAC; and All Other Deals] (Total count)
  • Quarterly Funding Amounts
    • Table 1-1: Total Quarterly Funding, by Type, Q1 2021-Q4 2021 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
    • Table 1-2: Total Quarterly Funding, by Type, Q1 2022-Q1 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
    • Figure 1-3: Total Quarterly Funding, Q1 2021- Q1 2023 ($M)
    • Figure 1-4: Total Quarterly Funding, by Type, Q1 2021-Q1 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] ($M)
  • Quarterly Funding Category Shares, Q1 2021 Through Q1 2023
    • Table 1-3: Total Quarterly Funding Share, by Type, 2021 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
    • Table 1-4: Total Quarterly Funding Share, by Type, Q1 2022-Q1 2023 [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
    • Figure 1-5: Q1 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
    • Figure 1-6: Q2 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
    • Figure 1-7: Q3 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
    • Figure 1-8: Q4 2022 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
    • Figure 1-9: Q1 2023 Funding Share, by Type of Funding [M&A; Venture Capital/Private; IPO/FPO; Collab; SPAC; and Strat inv] (%)
  • Quarterly Deal Counts by Category, Q1 2021 - Q1 2023
    • Table 1-5: Quarterly Count of Deals, By 2021 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)
    • Table 1-6: Quarterly Count of Deals, by Quarter Q1 2022-Q1 2023, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)
  • Growth in Collaborations, Manufacturing/Supply Chain Deals, Licensing, Distribution/ Co-Marketing Highlight Activity in Cell and Gene Therapy
    • Figure 1-10: Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (Total number)
  • A Look at Less Frequent CGT Deal Types
    • Figure 1-11: Lower Frequency Deal Types, by Quarter, by Category [Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number)
    • Figure 1-12: Merger/ Acquisition Amount, by Quarter [Q1 2021 - Q1 2023] ($M)
    • Figure 1-13: Venture Capital/Private Funding Round Amount, by Quarter [January 2021-January 2022] ($M)
    • Figure 1-14: IPO/FPO Amount, by Quarter [Q1 2021-Q1 2023] ($M)
    • Figure 1-15: SPAC Portion Amount, by Year and Q1 2023 ($M)
  • Synopsis of Most Active Deal-Making Companies
    • Table 1-7: Most Active Companies' Deal-Making Rankings, by Category, 2021-Q1 2023 (Rank)
    • Table 1-8: Most Active Companies in Overall Deals, Collaborations
    • Figure 1-16: Most Active Companies in Overall Deals, Collaborations

Chapter 2: Venture Capital & Private Funding

  • VC/Private Funding in Flux
    • Figure 2-1: Total Number of VC/ Private Funding Deals by Month, January 2021-March 2023 (Total count)
    • Figure 2-2: Average VC/ Private Funding Round Amount, By Quarter Q1 2021-Q1 2023 ($M)
    • Table 2-1: Regional Venture Capital/Private Funding, by Quarter Q1 2021-Q1 2023, [North America, Europe, APAC, Rest of World] ($M) (%)
    • Figure 2-3: Quarterly Venture Capital/Private Total Funding, Q1 2021- Q1 2023, by Region [North America, Europe, APAC, Rest of World] ($M)
    • Table 2-2: Regional Venture Capital/Private Funding Shares, by Quarter Q1 2021-Q1 2023, [North America, Europe, APAC, Rest of World] (%)
    • Figure 2-4: Regional Venture Capital/Private Funding Shares, by Quarter Q1 2021 Q1 2023, [North America, Europe, APAC, Rest of World] (%)
    • Figure 2-5: Venture Capital/Private Funding Round Amounts, By Quarter [Q1 2021-Q1 2023] ($M)
    • Table 2-3: Venture Capital/Private Fundraising Deals, Q1 2023
    • Table 2-4: Venture Capital/Private Fundraising Deals, Q4 2022
    • Table 2-5: Venture Capital/Private, Q3 2022
    • Table 2-6: Venture Capital/Private Fundraising Deals, Q2 2022
    • Table 2-7: Venture Capital/Private Fundraising Deals, Q1 2022

Chapter 3: Strategic Investments

  • Strategic Investments in Cell and Gene Therapy
    • Figure 3-1: Total Number of Strategic Investments, By Quarter [Q1 2021-Q1 2023] (Total count)
    • Figure 3-2: Average Strategic Investment Amount, By Quarter [Q1 2021-Q1 2023] ($M)
    • Figure 3-3: Total Strategic Investments, By Quarter [Q1 2021-Q1 2023] ($M)
    • Table 3-1: Strategic Investment Total Amounts, Counts, and Averages, by Quarter, Q1 2021 Q1 2023, ($M)
    • Table 3-2: Strategic Investments, January 2021-April 2023
  • Most Active Companies
    • Table 3-3: Most Active in Acquisition/Merger/ Strategic Investment
    • Figure 3-4: Most Active in Acquisition/Merger/ Strategic Investment

Chapter 4: IPOs, FPOs, & SPACs

  • North America Sees the Majority of Proceeds from IPOs, FPOs, SPACs
    • Figure 4-1: Total Number of IPOs/ FPOs, By Month [Jan 2021-Mar 2023] (Total count)
    • Figure 4-2: Average IPO/ FPO Proceeds, By Quarter [Q1 2021-Q1 2023] ($M)
    • Table 4-1: Quarterly IPO/ FPO Total Funding, Q1 2021 Q1 2023, by Region [North America, Europe, APAC] ($M)
    • Figure 4-3: Total IPO/ FPO Funding, By Quarter, by Region [Q1 2021-Q1 2023] ($M)
    • Table 4-2: Regional IPO/ FPO Funding Shares, by Quarter, Q1 2021 Q1 2023, [North America, Europe, APAC] (%)
    • Figure 4-4: Regional IPO/FPO Funding Shares, By Quarter, Q1 2021 Q1 2023 [North America, APAC, and Europe) (%)
    • Figure 4-5: IPO/FPO Amounts, By Quarter [Q1 2021-Q1 2023] ($M)
    • Table 4-3: Quarterly SPAC Funding Portion, Q1 2021-Q1 2023 ($M)
    • Figure 4-6: Quarterly SPAC Funding Portion Total and Average, Q1 2021-Q1 2023 ($M)
    • Table 4-4: IPO/FPO Deals, Q1 2023
    • Table 4-5: IPO/FPO Deals, Q4 2022
    • Table 4-6: IPO/FPO Deals, Q3 2022
    • Table 4-7: IPO/FPO Deals, Q2 2022
    • Table 4-8: IPO/FPO Deals, Q1 2022
    • Table 4-9: SPAC Portion, January 2021-Mar 2023 ($M)
    • Figure 4-7: SPAC Portion Amount, by Year, '21, '22, Q1 2023 ($M)

Chapter 5: Mergers & Acquisitions (M&A)

  • Growing Numbers of M&A, Despite Lower Average Value
    • Figure 5-1: Total Number of Mergers and Acquisitions, By Month [Jan 2021-Mar 2023] (Total Count)
    • Figure 5-2: Average Merger/Acquisition Amount, By Quarter [Q1 2021-Q1 2023] ($M)
    • Table 5-1: Quarterly Merger and Acquisition Values, Counts, and Averages, Q1 2021-Q1 2023 ($M) (Total count)
    • Figure 5-3: Merger/ Acquisition Transactions Global Total, By Quarter [Q1 2022- Q1 2023] ($M)
    • Figure 5-4: Merger/ Acquisition Amounts, by Quarter [Q1 2021- Q1 2023] ($M)
    • Table 5-2: Mergers and Acquisitions Announcements, Q1 2023 ($M)
    • Table 5-3: Mergers and Acquisitions, Q4 2022 ($M)
    • Table 5-4: Mergers and Acquisitions, Q3 2022 ($M)
    • Table 5-5: Mergers and Acquisitions, Q2 2022 ($M)
    • Table 5-6: Mergers and Acquisitions, Q1 2022 ($M)
  • Most Active Companies
    • Table 5-7: Most Active in Acquisition/Merger/Strategic Investment
    • Figure 5-5: Most Active in Acquisition/Merger/ Strategic Investment

Chapter 6: Technology/Research/Strategic Collaborations

  • CGT Market Sees a Broad Variety of Collaborations
    • Figure 6-1: Total Number of Tech/ Research/ Strategic Collaborations, By Month [Jan 2021-Mar 2023] (Total count)
    • Figure 6-2: Total Number of Collaborations with Upfront and/or Milestone Payments, By Quarter [Q1 2021-Q1 2023] ($M)
    • Table 6-1: Collaboration Upfront and Future/ Milestone Payments, Counts, Averages, Q1 2021-Q1 2023 ($M) (Total count)
    • Figure 6-3: Average Collaboration Upfront Payment, By Quarter [Q1 2021-Q1 2023] ($M)
    • Figure 6-4: Total Collaboration Upfront Payments, By Quarter [Q1 2021-Q1 2023] ($M)
    • Figure 6-5: Average Collaboration Future/ Milestone Payments, By Quarter [Q1 2021-Q1 2023] ($M)
    • Figure 6-6: Total Collaboration Future/ Milestone Payments, By Quarter [Q1 2021-Q1 2023] ($M)
    • Table 6-2: Technology/Research/Strategic Collaboration Deals, January 2022-April 2023
  • Most Active Companies
    • Table 6-3: Most Active in Research/Strategic Collaborations
    • Figure 6-7: Most Active in Research/Strategic Collaborations

Chapter 7: Licensing

  • Stable Levels of Licensing in the Cell and Gene Therapy Market
    • Figure 7-1: Total Number of Licensing Deals, By Month [Jan 2021-Mar 2023] (Total count)
    • Table 7-1: Licensing Deals, January 2022-April 2023
  • Most Active Companies
    • Table 7-2: Most Active Companies in Licensing Deals
    • Figure 7-2: Most Active Companies in Licensing Deals

Chapter 8: Manufacturing and Supply Chain

  • Major Growth in Manufacturing and Supply Chain Management Activity in CGT
    • Figure 8-1: Total Number of Supply/ Manufacturing Deals, By Month [Jan 2021-Mar 2023] (Total count)
    • Table 8-1: Manufacturing and Supply Chain Deals, January 2022-March 2023
  • Most Active Companies
    • Table 8-2: Most Active Companies in Manufacturing/Supply Deals
    • Figure 8-2: Most Active Companies in Manufacturing/Supply Deals

Chapter 9: Public Outreach, Education, & Philanthropy

  • CGT Market Focusing Less on Public Outreach, Patient/ Consumer/ Trainee Education, and Philanthropy
    • Figure 9-1: Total Number of Outreach/ Philanthropy/ Education Deals, By Month [Jan 2021-Mar 2023] (Total count)
    • Table 9-1: Outreach, Education, & Philanthropy Deals, January 2022-Apr 2023

Chapter 10: Distribution & Co-Marketing

  • A Look at CGT Distribution and Co-Marketing Deals
    • Figure 10-1: Total Number of Distribution/ Co-Marketing Deals, by Month [Jan 2021-Mar 2023] (Total count)
    • Table 10-1: Distribution & Co-Marketing Deals, January 2022-Mar 2023
  • Most Active Companies
    • Table 10-2: Most Active Companies in Distribution/Co-Marketing Deals
    • Figure 10-2: Most Active Companies in Distribution/Co-Marketing Deals

Chapter 11: Other - JV, Restructuring, Termination, Spinoffs

  • A Look at Other Types of Deals Impacting Cell and Gene Therapy
    • Figure 11-1: Total Number of JV, Restructuring, Termination, By Month [Jan 2021-Mar 2023] (Total count)
    • Table 11-1: Restructuring, JV, Termination, Spinoffs, January 2022-April 2023

Chapter 12: Other - New Facilities, Expansion; Real Estate

  • Expansion, New Facilities and Related Announcements
    • Table 12-1: New Facilities, Expansion; Real Estate Deals, January 2022-April 2023

Appendix: Cell and Gene Therapy Market Assessment

  • Market Outlook, 2022-2032
    • Table A-1: Cell and Gene Therapy Market Revenues by Product Type, 2022 and Projected 2027 and 2032 ($ millions)
    • Figure A-1: Cell and Gene Therapy Market Revenue Share, by Product Type [Cardiovascular-Blood, Dermatological, Musculoskeletal, Neurology, Oncology, Ophthalmic, Other Conditions] (%)
  • Regional Market
    • Table A-2: Cell and Gene Therapy Market by Country/Region [Europe, United States, Other Countries], 2022 Projected 2027 and 2032 ($ millions)
  • Products on the Market
    • Table A-3: Major Cell and Gene Therapy Product Approvals, FDA
  • Top Companies in Cell and Gene Therapy
    • Figure A-2: Leading Companies in Cell and Gene Therapy, By Company [Amylan, Bristol Myers, Dendreon, Gilead, Novartis, Smith and Nephew, Others]